Skip to main content
October 7, 2020

BERKELEY, CA – October 7, 2020 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, today announced that co-founder Jennifer Doudna, Ph.D., has been awarded the 2020 Nobel Prize in Chemistry. In awarding the prize to Dr. Doudna, the Swedish Academy cited her contributions to science for the co-development of CRISPR-Cas9, a genome editing breakthrough which has revolutionized biomedicine.

September 8, 2020
First allogeneic CAR-T cell therapy with PD-1 deleted by CRISPR genome editing cleared for Phase 1 clinical trials Upon initiation of the ANTLER Phase 1 clinical trial, CB-010 will be Caribou’s first clinical-stage product candidate
May 11, 2020

BERKELEY, Calif.--Caribou Biosciences, Inc., a leading CRISPR genome editing company, today announced the appointment of Cherry Thomas, MD, as Senior Vice President of Clinical Development. In this newly created position, Dr. Thomas will serve as Caribou’s clinical leader and oversee the advancement of the Company’s first allogeneic CAR-T cell therapy candidate, expected to start clinical trials later this year.

May 7, 2020
Agreement enables Caribou to utilize MaxCyte’s ExPERT® platform for its CRISPR gene-edited, allogeneic T cell therapy programs
February 19, 2020

BERKELEY, CA and RICHMOND, CA – February 19, 2020 – Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic engineered cell therapies.